Old polio vaccine may offer new shield against COVID-19

NCT ID NCT04445428

First seen Jun 27, 2026 ยท Last updated Jun 27, 2026

Summary

This study tested whether giving the oral polio vaccine (OPV) to adults over 50 in Guinea-Bissau could reduce their risk of getting sick or dying from COVID-19 and other infections. Researchers enrolled about 3,700 people and gave half the vaccine plus COVID-19 advice, while the other half got advice only. The idea is that live vaccines like OPV can boost the immune system broadly, not just against polio.

What this could mean

Our plain-language read of the trial. This is informational only โ€” not medical advice or a prediction.

Active substance
oral polio vaccine (OPV)
What this could lead to
If it works, this could point toward a cheap, widely available vaccine that offers some protection against COVID-19 and other infections.
What could go wrong
This is a completed Phase 4 trial in one African country, so results may not apply elsewhere. OPV is not a specific COVID-19 vaccine and may not provide strong or lasting protection.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Bandim Health Project

    Bissau, Guinea-Bissau

More trials for these conditions

Other studies related to the condition(s) this trial covers.